Loading clinical trials...
Loading clinical trials...
A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
Conditions
Interventions
Dabrafenib
Trametinib
Locations
41
United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
Santa Monica, California, United States
Novartis Investigative Site
Bethesda, Maryland, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
New York, New York, United States
Start Date
March 12, 2014
Primary Completion Date
December 10, 2021
Completion Date
December 10, 2021
Last Updated
August 21, 2023
NCT05673200
NCT05039801
NCT04929028
NCT05053971
NCT03375307
NCT05691465
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions